agilon health, inc. (NYSE:AGL) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of agilon health, inc. (NYSE:AGLGet Rating) have received a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $31.50.

Several research firms recently issued reports on AGL. TheStreet downgraded shares of agilon health from a “c-” rating to a “d+” rating in a research note on Thursday, August 18th. Truist Financial dropped their price target on shares of agilon health from $33.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, September 7th. BTIG Research initiated coverage on shares of agilon health in a research note on Friday, June 24th. They set a “neutral” rating on the stock. Royal Bank of Canada initiated coverage on shares of agilon health in a research note on Wednesday, September 14th. They issued an “outperform” rating and a $33.00 target price on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of agilon health in a research note on Monday, September 12th. They issued a “buy” rating and a $38.00 target price on the stock.

Insider Activity

In related news, insider Veeral Desai sold 106,357 shares of the business’s stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $22.50, for a total transaction of $2,393,032.50. Following the completion of the sale, the insider now owns 278,211 shares of the company’s stock, valued at approximately $6,259,747.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Veeral Desai sold 106,357 shares of the business’s stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $22.50, for a total transaction of $2,393,032.50. Following the completion of the sale, the insider now owns 278,211 shares of the company’s stock, valued at approximately $6,259,747.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Cd&R Investment Associates Ix, sold 11,337,500 shares of the business’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $24.35, for a total transaction of $276,068,125.00. Following the sale, the insider now directly owns 194,611,308 shares of the company’s stock, valued at approximately $4,738,785,349.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,897,283 shares of company stock worth $289,823,722. 3.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On agilon health

A number of institutional investors have recently modified their holdings of AGL. FMR LLC grew its position in shares of agilon health by 14.9% during the 2nd quarter. FMR LLC now owns 34,862,287 shares of the company’s stock valued at $761,043,000 after buying an additional 4,512,008 shares during the last quarter. Capital World Investors grew its position in agilon health by 13.0% in the 4th quarter. Capital World Investors now owns 35,865,953 shares of the company’s stock worth $968,381,000 after purchasing an additional 4,123,743 shares during the last quarter. Capital Research Global Investors grew its position in agilon health by 45.6% in the 4th quarter. Capital Research Global Investors now owns 8,331,369 shares of the company’s stock worth $224,947,000 after purchasing an additional 2,610,640 shares during the last quarter. Wellington Management Group LLP grew its position in agilon health by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company’s stock worth $470,953,000 after purchasing an additional 1,834,890 shares during the last quarter. Finally, Swiss National Bank bought a new position in agilon health in the 2nd quarter worth about $10,430,000.

agilon health Stock Performance

Shares of AGL stock opened at $23.51 on Thursday. The company’s fifty day simple moving average is $23.83 and its 200-day simple moving average is $22.11. agilon health has a 52 week low of $14.36 and a 52 week high of $28.76. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.04. The company has a market cap of $9.56 billion, a PE ratio of -83.96 and a beta of 1.86.

agilon health (NYSE:AGLGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). agilon health had a negative return on equity of 9.80% and a negative net margin of 4.99%. The firm had revenue of $670.13 million for the quarter, compared to analysts’ expectations of $648.74 million. During the same period last year, the firm earned ($0.06) EPS. As a group, equities research analysts anticipate that agilon health will post -0.17 EPS for the current year.

agilon health Company Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.

Further Reading

Analyst Recommendations for agilon health (NYSE:AGL)

Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.